Trubion Extends Research Period With Wyeth
Published: 22-Jun-2009
Wyeth to pay $3.3 million in exchange for committed research services
Wyeth has exercised its option under the terms of its collaboration agreement with Trubion, to extend the research period for an additional one-year period through Dec. 22, 2010.
Under the terms of the new agreement, Wyeth will have funding commitments of approximately $3.3 million in exchange for committed research services to Trubion.
Earlier in December 2005, Trubion and Wyeth entered into a collaboration for the development and worldwide commercialization of TRU-015 and other CD20-directed therapeutics.
Peter Thompson, President, CEO and Chairman, Trubion, said: We are pleased that Wyeth has extended the research period of our collaboration. Wyeth's ongoing commitment to the collaboration underscores the potential of our technology, and we look forward to continuing our efforts with Wyeth as we pursue the development of additional first-in-class and best-in-class compounds.
Delicious
Digg
Reddit
Stumble
Facebook
LinkedInNetwork Sites
Mail sent successfully
Suppliers To This Sector
Browse A-Z
White Papers
Browse A-Z
CaseBase Management
BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...
SafetyBase Interchange
BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...
ClinicalBase Trial
BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...
Reliable Prediction of White Plasma Levels
Our kinetics & metabolism experts can help you select and further develop your candidate d ...
Kinetics and Metabolism
Our kinetics & metabolism experts can help you select and further develop your candidate d ...
Drug Safety Evaluation
Our kinetics & metabolism experts can help you select and further develop your candidate d ...
